James West

James West

Managing Director
London Mergers & Acquisitions Healthcare +44 20 8126 5130
I strive to build long-term relationships with key individuals in my sectors of focus in order to provide the best advisory services for my clients.

As a member of the firm’s Healthcare Group, James advises mid-market company owners and investors on mergers and acquisitions (M&A). His focus spans the pharmaceutical and pharmaceutical services sectors, advising on both buy-sides and sell-sides. Specifically, he has advised on transactions covering the commercial, manufacturing and research; pharmaceutical products and generics and medical technology, devices and diagnostics sectors.

Over almost a decade in the industry, James has built up a network and is passionate in helping shape growth strategies for company owners.

Prior to joining Lincoln, James worked at Results International where he led the pharmaceutical services practice. Previously, he worked at KPMG in the healthcare M&A team.

James holds a Master of Pharmacy from Bath University and is a qualified Associate Chartered Accountant.

Perspectives featuring James West

What Price is Right? Trends and Opportunities for Private Equity in Pharma Market Access

The cost of developing new drugs is staggering. Among the top 20 global biopharmas, the average cost of developing a candidate from discovery through clinical trials to market was approximately… Read More

Investment Opportunities in Pharma: A Data-Driven Exploration of CDMO Appeal

The report discusses the current state of the contract development and manufacturing organization (CDMO) market within the pharmaceutical industry, emphasizing the increased interest from private equity (PE) investors. The pharmaceutical… Read More

Lincoln’s Latest

Lincoln’s Latest video series features experts from across industries, services and geographies, sharing perspectives on current trends, recent observations and future outlooks.

Discovering the Investment Opportunity in Pre-Clinical CROs

The process to bring a drug to market is likely to be extensive and costly, from the starting points of research and development (R&D) across all phases of clinical trials… Read More

Showing 1 – 4 of 6
Load More

News & Media featuring James West

Scrip Asks…What Does 2024 Hold for Biopharma?

James West, Managing Director in Lincoln’s Healthcare Group, recently discussed his expectations for the biopharma market in 2024 as part of Scrip’s series. Part One – Business Strategy and Leadership… Read More

Real Deals | Healthcare M&A Resilience

What trends have you seen in the last quarter in relation to valuations in the healthcare space? Matthew Lee: It’s early days to get an accurate read on valuations as… Read More

Lincoln International Announces Managing Director Promotions 2022

Lincoln International, a global investment banking advisory firm, is pleased to announce the promotion of six Directors to Managing Director (MD), effective January 1, 2023. “Each of these individuals contributes… Read More

In Vivo Pharma Intelligence | The Growth Path for Drug Discovery Partners

Originally published by In Vivo Pharma Intelligence on November 15, 2022 James West, Director in Lincoln’s Healthcare Group, explains the key trends and mergers and acquisitions (M&A) dynamics in the… Read More

Showing 1 – 4 of 7
Load More

Meet our Senior Team in Mergers & Acquisitions & Healthcare